Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds

Inclusion Criteria: * Written informed consent must be given * Patient ≥ 18 years old * Diagnosed with type I or type II diabetes mellitus * Glycosylated haemoglobin, HbA1c, ≤ 12% * Presence of diabetic foot ulcer or an amputation wound that meets following criteria: 1. Size of the wound 0,5 - 12 cm\^2 2. Wagner grade I or II 3. Wound is not infected 4. Wound present for at least 4 weeks * If multiple wounds are present, the biggest wound fitting the criteria is selected and the distance from other wounds must be at least 2 cm * If there is an amputation wound present, it can be used for the purpose of this study if it fits the rest of the criteria * Adequate perfusion (good, strong foot pulses). If foot pulses are weak, evaluation of perfusion pressures with Doppler ultrasound is performed. * Able to understand and comply with the requirements of the trial Exclusion Criteria: * Known history of alcohol or drug abuse * Use of any antibiotic medication within the last 7 days prior to the first application of study product * Patients presenting with Wagner Grade III or higher ulcer * Patients with serious concomitant disease (cancer, heart failure ( NYHA class IV), severe anemia (Hb\<100 g/L), neoplasia) * Any significant condition that may preclude the participant from the study (e.g. severe depression or psychiatric illness) * Patients that will require surgical procedure to treat their ischemic condition on the limb where the wound is present as assessed by the doctor * Excessive lymphedema that could interfere with wound healing (if there is mild edema treated with compression therapy the patient can be included) * Patients diagnosed with autoimmune connective tissues diseases * Previous treatment under this clinical protocol * Participation in another clinical trial up to 30 days before the randomization visit. * Receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, was known to interfere with, or affect the rate and quality of wound healing * Medical condition likely to require systemic corticosteroids during the study period * Allergic to shellfish, chitosan or one of ChitoCare product compounds * Immobile patients * Pregnant and lactating women * Significant increase in wound healing during run-in period (reduction of wound size area ≥ 40%) * BMI \> 39 kg/m2